Table 2.
Number of patients who presented the quality of care indicators for type 1 diabetes mellitus according to the guidelines in the two periods evaluated (n = 289)
| Quality of care indicator | 2019 | 2020 | P-value* |
|---|---|---|---|
| Assessment of distal simetric diabetic neuropathy | 152 (52.8) | 119 (41.3) | 0.004 |
| Assessment of albuminuria and / or serum creatininea | 247 (86.1) | 206 (71.8) | < 0.001 |
| Albuminuria (mg) | 6.0 (3.0–18.0) 0.9 (0.7–1.0) | 6.0 (4.0–14.0) 1.0 (0.8–1.2) | 0.93 < 0.001 |
| Mean creatinine (mg/dl) | |||
| HbA1ca | 263 (91.6) | 135 (47.0) | < 0.001 |
| Number of exams done | 3 (2–3) | 1 (1–2) | < 0.001 |
| HbA1c value (%) | 8.6 (7.8–9.8) | 8.6 (7.6–9.6) | 0.12 |
| HbA1c value (mmol/mol) | 70.0 (62.0–84.0) | 70.0 (60.0–81.0) | |
| Lipid profilea | 242 (84.3) | 266 (92.7) | < 0.001 |
| Total cholesterol (mg/dl) | 173.0 (151.0–200.0) | 178.0 (152.0–209.0) | < 0.001 |
| HDL cholesterol (mg/dl) | 56.0 (46.2–67.0) | 53.0 (45.0–64.2) | < 0.001 |
| LDL cholesterol(mg/dl) | 101.0 (77.3–124.5) | 104.8 (82.5–128.9) | < 0.001 |
| Triglyceride (mg/dl) | 78.5 (58.8–112.0) | 81.0 (60.5–108.0) | 0.39 |
| Retinopathy assessmentb | 172 (63.9) | 83 (30.9) | < 0.001 |
| Thyroid-stimulating hormone assessment | 262 (91.6) | 256 (89.5) | 0.080 |
Data presented as number (%) for categorical variables or median and interquartile range or mean and SD for continuous variables
HbA1c glycated hemoglobin, HDL high density lipoproteins, LDL low density lipoproteins
aNumber of tests assessed and median values based on the number of patients who presented quality of care indicators each year
bFive years of diagnosis: n = 271
*The p-value is given for the McNemar test for categorical variables and the Wilcoxon test for continuous variables